



# INSTITUTIONAL BIOSAFETY COMMITTEE

---

UNIVERSITY *of* WASHINGTON

## Meeting Minutes

**Date:** Wednesday, November 16, 2016

**Time:** 10:00 AM – 12:00 PM

**Location:** Foegen N-130A

- Members Present:**
1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
  2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
  3. Richard Grant, Washington National Primate Research Center
  4. Garry Hamilton (*Community Member*)
  5. Kevin Hybiske, Allergy and Infectious Diseases
  6. Stephen Libby, Laboratory Medicine (*IBC Chair*)
  7. Scott Meschke, Environmental & Occupational Health Sciences
  8. Jason Smith, Microbiology (*IBC Vice Chair*)
  9. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer*)
  10. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

### Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:04 am. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
  - The IBC Chair sought a motion to approve the minutes from the October 19, 2016 meeting.
  - A member made a motion to approve the October 19, 2016 minutes. Another member seconded the motion.
  - The committee voted unanimously to approve the October 19, 2016 meeting minutes.
4. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
  - a. Biosafety Officer Report
    - Dr. Lidstrom renewed a BUA involving recombinant non-pathogenic Risk Group 1 bacteria.
    - Dr. Trapnell added a new wildtype influenza virus strain to his approval. The influenza strain will be used in vitro at BSL-2 containment.
    - Dr. Jiang and Dr. Klavins each added the Pathology Flow Cytometry Core Facility to their respective BUA approvals.
    - Dr. Smedley received approval for baboon cytomegalovirus used in vitro.
    - Dr. West's BUA letter was amended to reflect the current room numbers associated with the UW Select Agent Program.
    - Dr. Sodora renewed a BUA involving non-recombinant SIV (simian immunodeficiency virus) used in macaques.
    - Dr. Pepper added human blood to her BUA approval.
    - The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
    - A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
    - The Committee unanimously voted to approve this month's Biosafety Officer Report.
5. **CATEGORY III-D AMENDMENTS**
  1. Chen, Eleanor, change, *Druggable pathways in rhabdomyosarcoma*
    - The biosafety officer presented the project.
    - Dr. Chen is already approved for human cells used in mice and AAV used in mice. The requested change is to administer human cells transduced with AAV to mice.
    - The assigned IBC member endorsed the biosafety officer's review.
    - The draft BUA letter was shown.
    - The lab recently passed the lab inspection and all of the required trainings have been completed.
    - The assigned IBC member made a motion to approve the draft BUA for Dr. Chen. A second is not needed since he endorsed the review.

- The Committee voted unanimously to approve the draft BUA for Dr. Chen.

## 6. INDIVIDUAL PROJECT REVIEWS

2. Di Stilio, Veronica, renewal, *Functional Evolution of Flower Organ Identity Genes in the basal Eudicot Thalictrum: Implications for transitions in breeding and pollination systems*
  - The assigned IBC Primary Reviewer presented the Primary Review. A UW faculty member with expertise in plants also assisted in the review of this project.
  - This is a renewal. The goal of the research is to characterize the genes underlying flower development and flower organ identity in an evolutionary context.
  - Transgenic plants and ferns are used. The experiments will result in transgenic fern spores. The work with the fern spores will be performed in a growth chamber, which will keep the spores contained. The fern species is tropical, and would not be able to cross or survive with native ferns if a loss of containment did occur.
  - A discussion occurred regarding the biosafety level. The designation P1 is used for plants, and BSL-1 is used for in vitro work.
  - The draft BUA letter was shown.
  - The lab has successfully passed the lab inspection and all of the required trainings have been completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Di Stilio. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Di Stilio.
3. Giachelli, Cecilia, renewal, *Renal Insufficiency and Vascular Disease*
  - The assigned IBC Primary Reviewer presented the Primary Review.
  - This is a renewal. Amphotropic and ecotropic gammaretroviral vectors are used in vitro. Human cells are also used.
  - The draft BUA letter was shown.
  - A question was raised about the IACUC protocol. This particular BUA does not involve administering any viral vectors or other agents to mice, but Dr. Giachelli does have other BUAs that involve animal work.
  - The lab has successfully passed the lab inspection and all of the required trainings have been completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Giachelli. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Giachelli.
4. Hu, Shiu-Lok, new, *mRNA-based Zika Vaccine*
  - The assigned IBC Primary Reviewer presented the Primary Review.
  - This is a new BUA from an established investigator.
  - An mRNA vaccine will be used in macaques. This work does not include the use of Zika virus or any other infectious viruses.
  - The work will be conducted at BSL-2.
  - The draft BUA letter was shown.
  - The lab has recently passed the lab inspection and all of the required trainings have been completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hu. A second is not needed since he is the Primary Reviewer.

- The Committee voted unanimously to approve the draft BUA for Dr. Hu.
5. Miller, Samuel, renewal, *Role of the *phoP* Regulon and Salmonella Virulence/Regulation of Salmonella Invasion of Epithelia/SPI2*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This is a renewal. The overall goal of the research is to understand the molecular and genetic mechanisms of Gram-negative bacterial pathogens, especially Salmonella.
  - Recombinant strains of *Acinetobacter baumannii* and *Salmonella Typhimurium* are used in mice. Several species of recombinant Risk Group 2 gram-negative bacteria are used in vitro.
  - The draft BUA letter was shown.
  - The lab successfully passed the lab inspection and all of the required trainings have been completed.
  - The IACUC protocol has not yet been submitted. The approval will not be sent until the biosafety officer has an opportunity to review the IACUC protocol.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Miller. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Miller, pending biosafety officer review of the IACUC protocol.
  - :
6. Oberst, Andrew, change, *Programmed Cell Death and Immunity*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This is a change request to add wildtype Zika virus, which will be administered to transgenic mice.
  - The Zika virus is not recombinant, but is used in a transgenic mouse model, so this work falls under section III-D.
  - The employees who work with Zika virus will receive in-person medical counseling as outlined in the Zika Medical Management Policy.
  - The IACUC protocol has not yet been submitted. The approval will not be sent until the biosafety officer has an opportunity to review the IACUC protocol.
  - The draft BUA letter was shown.
  - The lab has recently passed the lab inspection and all of the required trainings have been completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Oberst. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Oberst, pending biosafety officer review of the IACUC protocol.
7. Stevens, Kelly, new, *Regenerative Technologies*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This is a new project from an established principal investigator. The overall goal of the research is to develop cell-based treatments for patients with organ failure due to heart and liver disease.
  - Fourth-generation lentiviral vectors are used in mice and rats. Human induced pluripotent stem cells are also used in mice and rats.
  - The draft BUA letter was shown.

- The lab has recently passed the inspection, and all of the required trainings have been completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Stevens. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Stevens.
8. Wakimoto, Barbara, renewal, *Developmental Genetic Analysis of Fertilization Pathways in Drosophila*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The overall goal of the research is to understand the mechanisms responsible for interactions of the sperm and egg during fertilization in animals. The project uses male sterile mutants of the fruit fly *Drosophila melanogaster* to discover the molecules and cellular pathways responsible for sperm activation and paternal effects on early embryogenesis.
  - The work with transgenic fruit flies falls under section III-D of the NIH Guidelines.
  - The draft BUA letter was shown.
  - All required trainings have also been completed. The lab inspection is scheduled for later this week.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Wakimoto. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Wakimoto, pending successful completion of the lab inspection.
9. Waterston, Robert, renewal, *Single Cell Gene Expression in C. elegans*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The overall goal of the project is to identify when and where individual transcription factors are expressed during embryonic development of *C. elegans*. Plasmids are used, as well as wildtype and transgenic *C. elegans*.
  - An IBC reviewer clarified that *Caenorhabditis elegans* is a nematode, a type of roundworm.
  - The lab was inspected and was in excellent condition. The required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Waterston. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Waterston.

#### **LAB SAFETY INITIATIVE PRESENTATION:**

- The University of Washington is launching a two-year Laboratory Safety Initiative (LSI) as part of a national movement to build a better culture of safety in university research laboratories. This initiative is intended to lead to the development and implementation of services, approaches, best practices, and tools that significantly improve laboratory chemical safety throughout the University.
- A pilot group of 90 labs is working with EH&S on the initiative. These are labs with a rating of less than 75% on their most recent laboratory safety survey. These labs will be surveyed three times over a 24-month period.

**FOR YOUR INFORMATION:**

- 

**ISSUES FROM THE FLOOR & PUBLIC COMMENTS:**

There were no issues from the floor, and no public comments.

**MEETING ADJOURNED AT APPROXIMATELY      a.m.**